• Collaborations progressed with leading academic centres
• Further strengthening of intellectual property portfolio
• Successful Initial Public Offering (“IPO”) on AIM raising £7.5 million (gross) of new funding
• Highly experienced Board appointed

Alderley Park, 22 September 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces its maiden unaudited results for the six months ended 30 June 2021.

Please Read PDF RNS HERE